JP2018536687A5 - - Google Patents

Download PDF

Info

Publication number: JP2018536687A5
Authority: JP; Japan
Prior art keywords: alkyl; halo; phenyl; alkoxy; haloalkyl
Prior art date: 2016-12-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2018530001A

Other languages

English (en)

Japanese (ja)

Other versions

JP6811241B2 (ja

JP2018536687A (ja

Filing date

2016-12-08

Publication date

2020-01-23

2016-12-08 Application filed filed Critical

2016-12-08 Priority claimed from PCT/US2016/065504 external-priority patent/WO2017100390A1/en

2018-12-13 Publication of JP2018536687A publication Critical patent/JP2018536687A/ja

2020-01-23 Publication of JP2018536687A5 publication Critical patent/JP2018536687A5/ja

2021-01-13 Application granted granted Critical

2021-01-13 Publication of JP6811241B2 publication Critical patent/JP6811241B2/ja

Status Active legal-status Critical Current

2036-12-08 Anticipated expiration legal-status Critical

Links

125000000217 alkyl group Chemical group 0.000 claims 45
125000005843 halogen group Chemical group 0.000 claims 22
125000003545 alkoxy group Chemical group 0.000 claims 21
125000001188 haloalkyl group Chemical group 0.000 claims 20
125000004438 haloalkoxy group Chemical group 0.000 claims 19
125000001424 substituent group Chemical group 0.000 claims 19
239000001257 hydrogen Substances 0.000 claims 16
229910052739 hydrogen Inorganic materials 0.000 claims 16
150000001875 compounds Chemical class 0.000 claims 13
125000004093 cyano group Chemical group *C#N 0.000 claims 13
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
125000004076 pyridyl group Chemical group 0.000 claims 13
UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
125000002393 azetidinyl group Chemical group 0.000 claims 6
125000002757 morpholinyl group Chemical group 0.000 claims 6
-1 or benzodioxyl Chemical group 0.000 claims 6
125000004193 piperazinyl group Chemical group 0.000 claims 6
125000003386 piperidinyl group Chemical group 0.000 claims 6
125000000714 pyrimidinyl group Chemical group 0.000 claims 6
125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
150000002431 hydrogen Chemical class 0.000 claims 5
125000002768 hydroxyalkyl group Chemical group 0.000 claims 5
125000000842 isoxazolyl group Chemical group 0.000 claims 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
125000003226 pyrazolyl group Chemical group 0.000 claims 5
125000002098 pyridazinyl group Chemical group 0.000 claims 5
150000003839 salts Chemical class 0.000 claims 5
125000001544 thienyl group Chemical group 0.000 claims 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
125000003373 pyrazinyl group Chemical group 0.000 claims 4
125000000335 thiazolyl group Chemical group 0.000 claims 4
125000004414 alkyl thio group Chemical group 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
125000002541 furyl group Chemical group 0.000 claims 3
125000002883 imidazolyl group Chemical group 0.000 claims 3
125000001786 isothiazolyl group Chemical group 0.000 claims 3
229910052757 nitrogen Inorganic materials 0.000 claims 3
125000001715 oxadiazolyl group Chemical group 0.000 claims 3
125000002971 oxazolyl group Chemical group 0.000 claims 3
125000000168 pyrrolyl group Chemical group 0.000 claims 3
229940124597 therapeutic agent Drugs 0.000 claims 3
125000001113 thiadiazolyl group Chemical group 0.000 claims 3
125000004306 triazinyl group Chemical group 0.000 claims 3
125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
125000003118 aryl group Chemical group 0.000 claims 2
125000000000 cycloalkoxy group Chemical group 0.000 claims 2
125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 2
208000019622 heart disease Diseases 0.000 claims 2
125000001072 heteroaryl group Chemical group 0.000 claims 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
208000010125 myocardial infarction Diseases 0.000 claims 2
ZJMQIDCUWFQBBS-OAQYLSRUSA-N 1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=C(F)C=C(Cl)C=C2)C1=O ZJMQIDCUWFQBBS-OAQYLSRUSA-N 0.000 claims 1
QQPVLMVWMKXQHE-XMMPIXPASA-N 1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-[3-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1cccc(c1)-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)cc2F)C1=O QQPVLMVWMKXQHE-XMMPIXPASA-N 0.000 claims 1
OHLYBNSPTDBWII-OAQYLSRUSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)C1=C(C=CC=C1)C1=CC(F)=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O OHLYBNSPTDBWII-OAQYLSRUSA-N 0.000 claims 1
UBOJUPGIJLMJCN-JOCHJYFZSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-(2-methylsulfonylphenyl)phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)C1=C(C=CC=C1)C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O UBOJUPGIJLMJCN-JOCHJYFZSA-N 0.000 claims 1
LOSIFPMBGPRRNJ-HSZRJFAPSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O LOSIFPMBGPRRNJ-HSZRJFAPSA-N 0.000 claims 1
AJPPVEUXDAUQMA-OAQYLSRUSA-N 1-(4-chlorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1CCC[C@@H](NC(=O)NC2=CC=C(Cl)C=C2)C1=O AJPPVEUXDAUQMA-OAQYLSRUSA-N 0.000 claims 1
LHCDRRGUOGKMRW-JOCHJYFZSA-N 1-(5-chloropyridin-2-yl)-3-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)cn2)C1=O LHCDRRGUOGKMRW-JOCHJYFZSA-N 0.000 claims 1
AIDAYUXXQQPICM-OAQYLSRUSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O AIDAYUXXQQPICM-OAQYLSRUSA-N 0.000 claims 1
SMTNDFPSTGCTRT-JOCHJYFZSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O SMTNDFPSTGCTRT-JOCHJYFZSA-N 0.000 claims 1
SPCFTOQYHGQAQX-JOCHJYFZSA-N 1-(6-chloropyridin-3-yl)-3-[(3R)-1-[4-[3-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]urea Chemical compound CS(=O)(=O)NCc1cccc(c1)-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(Cl)nc2)C1=O SPCFTOQYHGQAQX-JOCHJYFZSA-N 0.000 claims 1
LBKZAJLYIZAXHD-HXUWFJFHSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-(5-methyl-1,2-oxazol-3-yl)urea Chemical compound Cc1cc(NC(=O)N[C@@H]2CCCN(C2=O)c2ccc(cc2)-c2ccccc2NS(C)(=O)=O)no1 LBKZAJLYIZAXHD-HXUWFJFHSA-N 0.000 claims 1
HIRCZQRIKKQTKV-HSZRJFAPSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cc2)C(F)(F)F)C1=O HIRCZQRIKKQTKV-HSZRJFAPSA-N 0.000 claims 1
VQOULAYTSCHUII-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[5-(trifluoromethyl)pyridin-2-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cn2)C(F)(F)F)C1=O VQOULAYTSCHUII-OAQYLSRUSA-N 0.000 claims 1
POGQSYOBRNXNIG-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[6-(trifluoromethyl)pyridin-3-yl]urea Chemical compound CS(=O)(=O)Nc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(nc2)C(F)(F)F)C1=O POGQSYOBRNXNIG-OAQYLSRUSA-N 0.000 claims 1
HBBUWMWLEWOSFT-OAQYLSRUSA-N 1-[(3R)-1-[4-[2-(methanesulfonamido)pyridin-3-yl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC=C(C=C1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O HBBUWMWLEWOSFT-OAQYLSRUSA-N 0.000 claims 1
VSVOTKNFGHDFPB-XMMPIXPASA-N 1-[(3R)-1-[4-[2-(methanesulfonamidomethyl)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NCc1ccccc1-c1ccc(cc1)N1CCC[C@@H](NC(=O)Nc2ccc(cc2)C(F)(F)F)C1=O VSVOTKNFGHDFPB-XMMPIXPASA-N 0.000 claims 1
VXJDKOGERHOGJG-HXUWFJFHSA-N 1-[(3R)-1-[5-(2-fluorophenyl)pyridin-2-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound FC1=C(C=CC=C1)C=1C=CC(=NC=1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O VXJDKOGERHOGJG-HXUWFJFHSA-N 0.000 claims 1
MUSFHYDVTYUBGU-OAQYLSRUSA-N 1-[(3R)-1-[5-[2-(methanesulfonamido)phenyl]pyridin-2-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C=1C=CC(=NC=1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O MUSFHYDVTYUBGU-OAQYLSRUSA-N 0.000 claims 1
YELGTUQEHZEBDY-JOCHJYFZSA-N 1-[(3R)-1-[6-[2-(methanesulfonamido)phenyl]pyridin-3-yl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CS(=O)(=O)NC1=C(C=CC=C1)C1=CC=C(C=N1)N1C([C@@H](CCC1)NC(NC1=CC=C(C=C1)C(F)(F)F)=O)=O YELGTUQEHZEBDY-JOCHJYFZSA-N 0.000 claims 1
XXTALGDGUPQNQI-OAQYLSRUSA-N 2-[4-[(3R)-3-[(4-chlorophenyl)carbamoylamino]-2-oxopiperidin-1-yl]-3-fluorophenyl]benzamide Chemical compound NC(=O)c1ccccc1-c1ccc(N2CCC[C@@H](NC(=O)Nc3ccc(Cl)cc3)C2=O)c(F)c1 XXTALGDGUPQNQI-OAQYLSRUSA-N 0.000 claims 1
206010002383 Angina Pectoris Diseases 0.000 claims 1
206010002388 Angina unstable Diseases 0.000 claims 1
206010007556 Cardiac failure acute Diseases 0.000 claims 1
206010007558 Cardiac failure chronic Diseases 0.000 claims 1
206010019280 Heart failures Diseases 0.000 claims 1
208000007814 Unstable Angina Diseases 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
230000001154 acute effect Effects 0.000 claims 1
230000001269 cardiogenic effect Effects 0.000 claims 1
208000029078 coronary artery disease Diseases 0.000 claims 1
230000006378 damage Effects 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000001153 fluoro group Chemical group F* 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
238000000034 method Methods 0.000 claims 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1

JP2018530001A 2015-12-10 2016-12-08 ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト Active JP6811241B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562265885P	2015-12-10	2015-12-10
US62/265,885		2015-12-10
PCT/US2016/065504 WO2017100390A1 (en)	2015-12-10	2016-12-08	Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Publications (3)

Publication Number	Publication Date
JP2018536687A JP2018536687A (ja)	2018-12-13
JP2018536687A5 true JP2018536687A5 (2)	2020-01-23
JP6811241B2 JP6811241B2 (ja)	2021-01-13

Family

ID=57590898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018530001A Active JP6811241B2 (ja)	2015-12-10	2016-12-08	ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト

Country Status (14)

Country	Link
US (2)	US10717708B2 (2)
EP (1)	EP3414227B1 (2)
JP (1)	JP6811241B2 (2)
KR (1)	KR102772801B1 (2)
CN (1)	CN108368046B (2)
AU (1)	AU2016366211B2 (2)
BR (1)	BR112018011046A2 (2)
CA (1)	CA3007972A1 (2)
EA (1)	EA034227B1 (2)
ES (1)	ES2901471T3 (2)
IL (1)	IL259791B (2)
MX (1)	MX386387B (2)
SG (1)	SG11201804589TA (2)
WO (1)	WO2017100390A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108348479A (zh) *	2015-11-24	2018-07-31	百时美施贵宝公司	靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病
EP3414227B1 (en)	2015-12-10	2021-11-24	Bristol-Myers Squibb Company	Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (ko) *	2017-06-09	2024-01-09	브리스톨-마이어스 스큅 컴퍼니	피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2018227067A1 (en)	2017-06-09	2018-12-13	Bristol-Myers Squibb Company	Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US11008301B2 (en)	2017-06-09	2021-05-18	Bristol-Myers Squibb Company	Piperidinone formyl peptide 2 receptor agonists
CN110997653B (zh)	2017-06-09	2023-06-06	百时美施贵宝公司	芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
US10676431B2 (en)	2018-03-05	2020-06-09	Bristol-Myers Squibb Company	Phenylpyrrolidinone formyl peptide 2 receptor agonists
AR114383A1 (es) *	2018-03-09	2020-08-26	Gruenenthal Gmbh	Piperidinas o piperidonas sustituidas con urea y fenilo
CN113166134B (zh)	2018-11-26	2024-06-14	百时美施贵宝公司	作为甲酰肽2受体激动剂的吡咯烷酮衍生物
WO2020257161A1 (en) *	2019-06-18	2020-12-24	Bristol-Myers Squibb Company	Biaryl dialkyl phosphine oxide fpr2 agonists
EP3789378A1 (en) *	2019-09-06	2021-03-10	Grünenthal GmbH	Piperidines or piperidones substituted with urea and heteroaryl
IL299680A (en)	2020-07-09	2023-03-01	Bristol Myers Squibb Co	Pyrazolone formyl peptide 2 receptor agonists
JP7802765B2 (ja) *	2020-08-12	2026-01-20	ブリストル－マイヤーズスクイブカンパニー	オキソピロリジン尿素ｆｐｒ２アゴニスト

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6706712B2 (en)	2000-12-20	2004-03-16	Bristol-Myers Squibb Pharma Company	Cyclic derivatives as modulators of chemokine receptor activity
US7678913B2 (en) *	2004-12-07	2010-03-16	Portola Pharmaceuticals, Inc.	Ureas as factor Xa inhibitors
BR112015021392B1 (pt) *	2013-03-06	2021-11-16	Allergan, Inc	Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
ES2752733T3 (es)	2013-11-28	2020-04-06	Kyorin Seiyaku Kk	Derivados de urea deuterados o marcados isotópicamente o sales farmacológicamente aceptables de los mismos útiles como agonistas de FPRL-1
JP6746613B2 (ja) *	2015-05-27	2020-08-26	杏林製薬株式会社	ウレア誘導体、またはその薬理学的に許容される塩
JP6746614B2 (ja)	2015-05-27	2020-08-26	杏林製薬株式会社	ウレア誘導体、またはその薬理学的に許容される塩
CN108348479A (zh)	2015-11-24	2018-07-31	百时美施贵宝公司	靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病
EP3414227B1 (en) *	2015-12-10	2021-11-24	Bristol-Myers Squibb Company	Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102623473B1 (ko) *	2017-06-09	2024-01-09	브리스톨-마이어스 스큅 컴퍼니	피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
WO2018227067A1 (en)	2017-06-09	2018-12-13	Bristol-Myers Squibb Company	Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
CN110997653B (zh)	2017-06-09	2023-06-06	百时美施贵宝公司	芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂
US11008301B2 (en)	2017-06-09	2021-05-18	Bristol-Myers Squibb Company	Piperidinone formyl peptide 2 receptor agonists

2016
- 2016-12-08 EP EP16816564.5A patent/EP3414227B1/en active Active
- 2016-12-08 KR KR1020187019246A patent/KR102772801B1/ko active Active
- 2016-12-08 US US15/776,933 patent/US10717708B2/en active Active
- 2016-12-08 BR BR112018011046A patent/BR112018011046A2/pt active Search and Examination
- 2016-12-08 ES ES16816564T patent/ES2901471T3/es active Active
- 2016-12-08 WO PCT/US2016/065504 patent/WO2017100390A1/en not_active Ceased
- 2016-12-08 EA EA201891143A patent/EA034227B1/ru not_active IP Right Cessation
- 2016-12-08 SG SG11201804589TA patent/SG11201804589TA/en unknown
- 2016-12-08 AU AU2016366211A patent/AU2016366211B2/en not_active Ceased
- 2016-12-08 CA CA3007972A patent/CA3007972A1/en not_active Abandoned
- 2016-12-08 CN CN201680072467.4A patent/CN108368046B/zh active Active
- 2016-12-08 MX MX2018006635A patent/MX386387B/es unknown
- 2016-12-08 JP JP2018530001A patent/JP6811241B2/ja active Active
2018
- 2018-06-04 IL IL259791A patent/IL259791B/en unknown
2020
- 2020-06-11 US US16/898,889 patent/US11530183B2/en active Active

Publication	Publication Date	Title
JP2018536687A5 (2)	2020-01-23
HRP20210094T1 (hr)	2021-03-05	POSTUPAK PRIPRAVE DERIVATIVA OKSAZOLO[4,5-b]PIRIDINA I TIAZOLO[4,5-b]PIRIDINA KAO INHIBITORA IRAK4 NAMIJENJENIH LIJEČENJU RAKA
JP2006509715A5 (2)	2006-05-11
JP2014516074A5 (2)	2015-07-09
JP2019518036A5 (2)	2020-11-12
JP2019530695A5 (2)	2020-11-12
IL263511A (en)	2019-01-31	1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
JP2014511869A5 (2)	2015-05-21
JP2011502958A5 (2)	2011-06-30
JP2016519156A5 (2)	2017-06-29
JP2018535999A5 (2)	2020-01-16
RU2020113350A (ru)	2021-10-15	Модуляторы белка регулятора трансмембранной проводимости при муковисцидозе и способ применения
JP2016530213A5 (2)	2017-10-26
RU2016108753A (ru)	2017-09-19	Ингибиторы ферментов
JP2022551422A5 (2)	2023-08-24
JP2016503009A5 (2)	2017-01-05
RU2012154308A (ru)	2014-06-27	Пиперидинил-замещенные лактамы как модуляторы gpr119
EP2238133A2 (en)	2010-10-13	Fungicidal amides
JP2013501720A5 (2)	2015-05-28
JP2016516043A5 (2)	2017-04-13
JP2012525349A5 (2)	2013-06-20
NZ609955A (en)	2015-05-29	Sgc stimulators
JP2017502049A5 (2)	2018-02-08
RU2015100942A (ru)	2016-08-10	Производное пиперидинилпиразолпиридина
IL273000B2 (en)	2023-08-01	Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)